STOCK TITAN
  1. Home
  2. News
  3. BMRN

BioMarin to Hold Virtual R&D Day at 11:00am ET Today

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

SAN RAFAEL, Calif., Nov. 30, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host a virtual R&D Day beginning at 8:00am PT/11:00am ET today, Tuesday, November 30, 2021.  BioMarin management and external experts will provide an update to the investment community on the Company's earlier-stage development portfolio, which is focused on translating genetic discoveries into transformative medicines.

Video Webcast and Live Q&A

Interested parties may access the video presentation that will include audio and slides of the presentations via YouTube using this link: https://youtu.be/05iCxYehS-c. A replay of the meeting will be archived on BioMarin's IR web site.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare genetic diseases. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com.  Information on such website is not incorporated by reference into this press release.

BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.

Contacts:


Investors 

Media 

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-hold-virtual-rd-day-at-1100am-et-today-301433892.html

SOURCE BioMarin Pharmaceutical Inc.

Stock BMRN logo
BioMarin Pharmaceuticals Inc

NASDAQ:BMRN

BMRN Rankings

#613 Ranked by Market Cap
#2446 Ranked by Stock Gains
N/A Ranked by Dividends

BMRN Latest News

Apr 24, 2024
BioMarin Reports Record Financial Results for the First Quarter 2024
Apr 10, 2024
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
Mar 12, 2024
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Mar 7, 2024
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
Mar 1, 2024
BioMarin Scheduled to Participate in March Investor Conferences

BMRN Stock Data

15.33B
187.23M
0.84%
100.76%
1.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NOVATO

About BMRN

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment